Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Evaluation of the Promega Maxwell® CSC and the Maxwell® CSC DNA FFPE Kit Poster

Part # PS234


Jeffrey R. Franz, BS1, Douglas Horejsh, PhD1, William M. Rehrauer, Ph.D2, Molly Accola, Ph.D2
1Promega Corporation, 2800 Woods Hollow Rd. Madison, WI; 2University of Wisconsin School of Medicine and Public Health Department of Pathology and Laboratory Medicine 600 Highland Ave. Madison, WI.

Personalized medicine for oncology patients is increasingly based upon mutation detection in cancerous tissues, typically stored as Formalin Fixed Paraffin Embedded (FFPE) tissues. An important component of the workflow needed for biomarker discovery is a DNA extraction method that produces high quality DNA, suitable for high resolution downstream analysis, including next generation sequencing. FFPE samples are difficult samples for molecular labs as the fixation process causes DNA fragmentation and protein-DNA cross linking. Frequently the tissues also contain inhibitors and/or quenching substances that must be removed in the extraction process. In this research study, we provide a side-by-side evaluation of the Promega Maxwell® CSC DNA FFPE automated extraction and the Roche Life Sciences MagNaPure method for isolating DNA from FFPE tissues of various tumor types.

Printed in USA.